Background and objectives Data from observational and interventional studies provide discordant results regarding the relationship between creatinine increase after renin-angiotensin system inhibition (RASi) and adverse outcomes. We compared health outcomes among patients with different categories of increase in creatinine upon initiation of RASi in a large population-based cohort. Design, setting, participants, & measurements We performed a retrospective analysis of the Stockholm CREAtinine Measurements database, which contains complete information on diagnoses, medication dispensation claims, and laboratory test results for all Stockholm citizens accessing health care. Included were 31,951 adults initiating RASi during 2007–2011 with available pre- and postinitiation creatinine monitoring. Multivariable Cox regression was used to compare mortality, cardiovascular and ESKD events among individuals with different ranges of creatinine increases within 2 months after starting treatment. Results In a median follow-up of 3.5 years, acute increases in creatinine were associated with mortality (3202 events) in a graded manner: compared with creatinine increases <10%, a 10%–19% increase
Archivi categoria: AKI
Association of Acute Increases in Plasma Creatinine after Renin-Angiotensin Blockade with Subsequent Outcomes | American Society of Nephrology
Individuals taking a certain number of NSAIDs each month had greater risks of acute kidney injury and chronic kidney disease.
Uno studio firmato da un team dell’Università di Firenze e dell’ospedale pediatrico Meyer rivoluziona le conoscenze sul danno renale acuto (fino a qualche anno fa definito insufficienza renale acuta),
Intravascular iodinated contrast has historically been considered a risk factor for acute kidney injury (AKI), particularly among individuals with underlying chronic kidney disease (1). Recent studies, however, have suggested that incidence of contrast-induced nephropathy (CIN) may not be as frequent as previously thought (2,3). In this commentary, we argue that contrast material can often be safely used without increased risk of AKI, even among individuals with underlying kidney disease.
Myocardial infarction patients who underwent percutaneous coronary intervention had an AKI rate similar to those who did not have the procedure.
Early and late initiation of renal replacement therapy for AKI in critically ill patients are associated with similar long-term risks.